Anti-wrinkle face cream ingredient (SNAP-8 / Acetyl Glutamyl Heptapeptide-3)
A synthetic peptide added to cosmetic creams that may relax facial muscles and soften the look of fine lines and wrinkles; a legal cosmetic ingredient worldwide, not an approved drug.
- Class
- Cosmetic peptide — SNARE-complex competitive antagonist
- Status
- Not FDA-approved as a drug. Permitted cosmetic ingredient in the US, EU, UK, Canada, Australia, Japan, and most major markets.
- Best-supported effect
- Competitive inhibition of SNARE complex assembly in vitro; real-world wrinkle-reduction effect in independent studies is modest and difficult to distinguish from vehicle controls.
- Main caveat
- Direct human clinical evidence on SNAP-8 specifically is sparse — the compiled source records no SNAP-8-specific human RCTs; most cited human trial data applies to the parent hexapeptide Argireline, not the octapeptide; manufacturer-sponsored efficacy claims substantially exceed what independent literature has reproduced.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Snapshot
Class: Cosmetic peptide — SNARE-complex competitive antagonist
Evidence tier: In vitro / assay evidence
Status: Not FDA-approved as a drug. Permitted cosmetic ingredient in the US, EU, UK, Canada, Australia, Japan, and most major markets.
Best-supported effect: Competitive inhibition of SNARE complex assembly in vitro; real-world wrinkle-reduction effect in independent studies is modest and difficult to distinguish from vehicle controls
Main caveat: Direct human clinical evidence on SNAP-8 specifically is sparse — Research no SNAP-8-specific human RCTs; most cited human trial data applies to the parent hexapeptide Argireline, not the octapeptide; manufacturer-sponsored efficacy claims substantially exceed what independent literature has reproduced
What this is
SNAP-8 (acetyl octapeptide-3, also listed under INCI as acetyl glutamyl heptapeptide-3 and acetyl octapeptide-1) is an eight-amino-acid synthetic cosmetic peptide developed by Lipotec S.A. in Spain in the 2000s as a second-generation extension of Argireline (acetyl hexapeptide-3). It is designed to mimic the N-terminal region of SNAP-25, a synaptic protein that botulinum toxin cleaves to disable neuromuscular junction signaling. The marketed hypothesis is that SNAP-8 competitively displaces SNAP-25 from the SNARE complex, partially reducing acetylcholine release and thereby softening expression-line muscle contractions — a topical cosmetic version of the Botox concept at a vastly smaller scale. Lipotec was acquired by Lubrizol in 2012 and the ingredient continues to be marketed through that umbrella. SNAP-8 is not an approved drug; it is a cosmetic ingredient sold in creams and serums. Independent peer-reviewed human trial data on the octapeptide specifically is sparse; the better-evidenced molecule in this category is the parent hexapeptide Argireline.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | Not present for SNAP-8 directly | No human RCTs or controlled trials on SNAP-8 specifically are identified in the available literature; the human clinical literature in this category centers on the related hexapeptide Argireline (acetyl hexapeptide-3/8) |
| Animal | None identified | No animal-model in vivo studies on SNAP-8 specifically are identified in the available literature |
| In vitro | Moderate | SNARE complex interaction and reduced vesicle fusion are confirmed in cell assays; cytotoxicity data shows low cytotoxicity for the class at standard cosmetic concentrations |
| Computational | None identified | No computational or docking data identified |
| Mechanism | Plausible — delivery-limited | SNARE complex biology is well characterized and SNAP-25 competitive inhibition is a validated pathway concept; the critical uncertainty is pharmacokinetic: whether topical delivery of a hydrophilic octapeptide achieves meaningful concentrations at the neuromuscular junction through intact skin |
Several human clinical references in the available literature — including microneedle peptide studies, multi-peptide combination trials, and independent Argireline RCTs — assess related SNARE-targeting peptide formulations, not SNAP-8 as a single-ingredient intervention. These are cited as analog and class context only. the available literature source breakdown explicitly records "Human RCT: 0" for SNAP-8 specifically.
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Inhibits SNARE complex formation in vitro | Supported (in vitro) | In vitro | High — mechanism confirmed in cell assay systems; in vitro confirmation does not establish skin penetration or clinical wrinkle-reduction |
| Reduces wrinkle depth by up to 63% with daily topical use | Weak — manufacturer-sponsored only | In vitro / manufacturer | High — the 63% figure derives from manufacturer-sponsored Lipotec/Lubrizol studies with small samples and proprietary methods; independent studies show far smaller effects, typically single-digit percentage changes difficult to distinguish from vehicle controls |
| Comparable to botulinum toxin without injections | Contradicted / not established | None | High — botulinum toxin enzymatically cleaves SNAP-25 producing 50–80% wrinkle reduction within days; SNAP-8 produces marginal reversible surface-texture improvement at best; the mechanisms share vocabulary but not scale; published literature explicitly characterizes the marketing framing as misleading |
| Safe for topical cosmetic use at standard formulation concentrations | Supported (topical cosmetic use) | In vitro | Medium — no meaningful adverse signals at standard concentrations; cytotoxicity is low; multi-year long-term safety data not individually extracted |
| Outperforms Argireline due to its two additional amino acids | Weak — not supported by clinical evidence | None | High — the superiority claim is a marketing premise unsupported by any head-to-head clinical trial; in vitro binding rationale does not translate to demonstrated in vivo superiority when transdermal delivery is the rate-limiting step |
Assay conditions
This section reports concentrations or conditions used in assays. It does not establish animal or human exposure.
| Context | System | Assay condition | Timepoint | Endpoint | Limitation |
|---|---|---|---|---|---|
| In vitro cell assay | Cell-based SNARE complex assembly system | Competitive peptide incubation at assay concentrations | not individually extracted | Vesicle fusion inhibition; SNARE complex interaction | In vitro results do not establish skin penetration depth, tissue concentration at the neuromuscular junction, or clinical effect magnitude |
| Cytotoxicity assay | Human skin fibroblast culture | Peptide exposure at standard cosmetic concentrations | not individually extracted | Cell viability; anti-senescence markers | Establishes cosmetic-grade cytotoxicity profile, not therapeutic efficacy |
| Manufacturer-sponsored cosmetic study | Human subjects (small sample; manufacturer-controlled) | 10% SNAP-8 in topical vehicle, twice-daily application | 28 days | Wrinkle depth by proprietary measurement method | Industry-sponsored; small samples; methodological limitations; effect sizes not reproduced in independent literature; listed as tested conditions, not validated clinical outcomes |
Assay limitations
- In vitro SNARE complex inhibition does not establish that topical SNAP-8 reaches the neuromuscular junction at clinically relevant concentrations through intact skin. The rate-limiting step is delivery, not receptor affinity.
- Manufacturer-sponsored studies use proprietary measurement methods with small samples and have not been independently replicated at the reported effect sizes.
- No head-to-head comparisons with vehicle-only controls matched for standard moisturizer effects are identified in the available literature.
- The additional two amino acids in SNAP-8 relative to Argireline increase molecular weight and hydrophilicity — both of which work against transdermal penetration — making the delivery barrier harder for the octapeptide than for the parent hexapeptide.
- Long-term safety data across multi-year continuous topical use is not individually extracted.
Regulatory status
| Region / body | Status | Notes |
|---|---|---|
| US (FDA) | Not approved as a drug. Permitted cosmetic ingredient. | INCI-listed as acetyl octapeptide-3; regulated under FDA cosmetic law; legal in over-the-counter skincare without prescription; labels limited to cosmetic appearance claims; no drug approval for any indication |
| EU | Permitted cosmetic ingredient | Listed in CosIng database; no concerns at typical formulation concentrations per source |
| UK, Canada, Australia, Japan | Permitted cosmetic ingredient | per available sources; no concerns noted at formulation concentrations |
| WADA | Not listed on Prohibited List | Topical cosmetic peptides have negligible systemic exposure; not a realistic doping concern; per available sources, not independently refreshed in this card |
| Injectable use (any jurisdiction) | No authorized category exists | Cosmetic SNAP-8 preparations are not sterile injectable products; injecting cosmetic peptide products carries documented infection risk — published case reports exist for related cosmetic peptides causing serious facial infection after unlicensed injection |
Mechanism
SNAP-8 is designed to act as a competitive antagonist of SNAP-25 within the SNARE complex — the protein machinery that controls vesicle fusion and acetylcholine release at neuromuscular junctions. By mimicking the N-terminal region of SNAP-25, SNAP-8 partially occupies SNARE complex binding sites, inhibiting vesicle fusion and reducing the intensity of muscle contraction. This is a reversible, concentration-dependent, competitive effect that operates only while peptide is present.
The SNARE complex biology underlying this hypothesis is well established, and SNAP-25 competitive inhibition is a validated pathway concept from the botulinum toxin literature. The critical uncertainty is pharmacokinetic rather than mechanistic: whether topical application of a hydrophilic octapeptide can cross the stratum corneum and reach the neuromuscular junction at concentrations sufficient to produce a meaningful competitive effect. the available literature consistently identifies this delivery gap as the primary limiter separating the in vitro mechanism from real-world effect size.
The botulinum toxin comparison is mechanistically misleading by scale: botulinum toxin enters nerve terminals and enzymatically cleaves SNAP-25 proteolytically, permanently disabling SNARE complex formation until new protein is synthesized — producing 50–80% dynamic wrinkle reduction within days from a single injection, lasting 3–4 months. SNAP-8's mechanism shares the pathway vocabulary without the magnitude, reversibility, or delivery precision.
Chemistry
| Field | Value |
|---|---|
| Peptide name | SNAP-8; Acetyl Octapeptide-3; Acetyl Glutamyl Heptapeptide-3; Acetyl Glutamyl Heptapeptide-1; Acetyl Octapeptide-1 |
| Sequence | Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂ |
| Length | 8 amino acids |
| Topology | Linear |
| N-terminal modification | Acetyl group (Ac-) |
| C-terminal modification | Amide (-NH₂) |
| Molecular formula | C₄₁H₆₃N₁₁O₁₃ |
| Molecular weight | 893.99 Da |
| CAS | 868844-74-0 |
| Half-life | Not well characterized; topical application context with limited systemic exposure |
| Origin | Developed by Lipotec S.A. (Spain) as successor to acetyl hexapeptide-3 (Argireline); acquired by Lubrizol in 2012; marketed through Pentapharm/DSM cosmetic-ingredient channels |
| Sequence confidence | Needs review — sequence sourced from RP section of the compiled bundle; not cross-referenced against primary chemistry literature in this card |
Design context: SNAP-8 extends the six-amino-acid Argireline scaffold (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂) by two additional residues (Ala-Asp). The marketing premise was tighter SNARE complex binding and longer-acting effect; the consequence is increased molecular weight and hydrophilicity, which reduce transdermal penetration relative to the parent hexapeptide.
Open questions
- Direct SNAP-8 human trials: No published controlled human clinical trials on SNAP-8 as a single-ingredient intervention are identified in the available literature. This is the central evidence gap for the molecule.
- Superiority over Argireline: The core marketing claim is that the octapeptide outperforms the hexapeptide through improved SNARE complex binding. No head-to-head clinical trial in the available literature supports this; in vitro binding rationale is not a substitute for in vivo comparison when delivery is the rate-limiting variable.
- Real-world skin penetration quantification: Delivered concentration of SNAP-8 at the neuromuscular junction from commercial formulations is uncharacterized. Vehicle-to-vehicle differences in penetration likely dominate outcome variability more than nominal label concentration.
- Long-term efficacy and safety: Most published work spans 28-day windows. Multi-month and multi-year continuous use data — for either safety or sustained wrinkle-depth benefit — are not individually extracted.
- Responder phenotypes: Clinical response variability is described anecdotally in available literature but has not been characterized against skin thickness, baseline muscle mass, formulation vehicle, or genetic factors.
- Stacking with Argireline: Whether co-formulating SNAP-8 and Argireline produces additive SNARE inhibition or redundant target occupancy is an open question without published controlled evidence. If skin penetration is the bottleneck, co-formulation may not produce additive benefit.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does this peptide block the full signal that causes muscle movement, or just a small corner of it?
If the peptide only latches onto one section of the target instead of the whole thing, there is a built-in limit to how much it can reduce fine lines, no matter the dose. Understanding that ceiling would tell formulators exactly what to expect and why making the molecule bigger has not made it noticeably stronger in practice.
Could a peptide sold for wrinkles also reduce redness and itch by stopping skin immune cells from releasing irritants?
If this holds, SNAP-8 might ease symptoms in sensitive or reactive skin by limiting histamine release from immune cells in the dermis, giving it a measurable anti-inflammatory use case that could be tested in a clinic. That would matter for people with chronic skin irritation or mild allergic reactions, not just those seeking cosmetic smoothing.
Does this peptide need to touch a cell membrane to become active, and could the right carrier deliver it already switched on?
If the peptide only works after folding against a lipid surface, most of it applied in a water-based cream could be inactive by the time it reaches its target. Packaging it inside a lipid nanoparticle or liposome could potentially pre-fold it, which might meaningfully improve how well the ingredient performs in real formulations.
Can a targeted chemical modification make this peptide absorb through skin better, turning a so-so cosmetic ingredient into something that actually reaches its target?
Poor absorption through the outer skin layer is widely considered the main reason SNAP-8 underperforms in studies. If modifying just the two outer amino acids makes it cross that barrier more easily while leaving the active part intact, it could convert a delivery-limited ingredient into one with a real, verifiable effect for people using anti-aging topicals.
▸full evidence table1 metrics
| metric | value | tool |
|---|---|---|
| ranking score | 0.739276111125946 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | none_monomer |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-23 |
▸citationbibtex
@peptide{pep10765,
sequence = {EEMQRRNL},
target = {cosmeceutical},
author = {peptidemodel},
year = {2026},
status = {computed}
}